Allergy Therapeutics (LON:AGY) Share Price Crosses Below 200-Day Moving Average – Here’s What Happened

Allergy Therapeutics plc (LON:AGY)’s stock price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 10.56 and traded as low as GBX 9.33. Allergy Therapeutics shares last traded at GBX 9.50, with a volume of 294,853 shares.

Allergy Therapeutics Price Performance

The company has a market capitalization of £614.26 million, a PE ratio of -10.00, a price-to-earnings-growth ratio of -30.70 and a beta of 0.89. The stock’s 50-day moving average is GBX 10.43 and its two-hundred day moving average is GBX 10.58. The company has a current ratio of 1.13, a quick ratio of 1.48 and a debt-to-equity ratio of 629.58.

Allergy Therapeutics (LON:AGY) last released its earnings results on Tuesday, March 31st. The company reported GBX (0.38) earnings per share for the quarter. Allergy Therapeutics had a positive return on equity of 409.00% and a negative net margin of 85.46%.The business had revenue of GBX 3,628 million for the quarter. On average, equities analysts predict that Allergy Therapeutics plc will post -2.56 EPS for the current year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.